Despite the increasing prevalence of neurodegenerative diseases in our ageing population, disease-modifying therapies remain elusive. As the mechanisms underlying neurodegeneration are poorly understood, these diseases are not especially amenable to target-based drug screening strategies. Here, Khurana et al. present phenotypic screening as an alternative drug discovery approach, and discuss how insights from a simple eukaryote, baker's yeast, are driving research in patient-derived neurons.
- Vikram Khurana
- Daniel F. Tardiff
- Susan Lindquist